Cardiac amyloidosis is a progressive, and underdiagnosed rare disease that leads to heart failure. Credit: Tumisu from Pixabay.

Health technology company Anumana and Pfizer have signed a multi-year agreement to develop an artificial intelligence electrocardiogram (AI-ECG) algorithm for the early detection of cardiac amyloidosis.

Under the deal, Anumana will carry out a clinical validation trial and seek De Novo classification for the new AI-ECG algorithm as a Software-as-a-Medical-Device (SaMD).

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The new AI-ECG algorithm will be designed for detecting patients who may be at risk of cardiac amyloidosis, which is a progressive, and underdiagnosed rare disease that leads to heart failure.

Anumana will also obtain regulatory approval for the algorithm as a SaMD to detect cardiac amyloidosis in Europe, Japan, and the US.

Anumana chief business officer David McMullin said: “The challenge in diagnosing cardiac amyloidosis can prevent patients from getting treatment while the disease continues to progress.

“We believe this collaboration will demonstrate the power of Anumana’s AI-ECG algorithms to help clinicians intervene earlier, giving them greater ability to improve patient outcomes and prolong lives.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The company stated that the research deal with Pfizer will help deepen its efforts in implementing AI-enabled early detection software, which can help in revealing the signals from ECGs that cannot be interpreted by humans.

The non-invasive, painless 100-year-old ECG test gives the potential to AI-ECG algorithms to reach more patients earlier.

Founded last year, Anumana licensed AI-ECG algorithms from Mayo Clinic for low ejection fraction, hyperkalemia, and pulmonary hypertension.

All the algorithms have received breakthrough device designation from the US Food and Drug Administration (FDA).

Mayo Clinic Cardiovascular Medicine Department chair Paul Friedman said: “AI-ECG solutions alert clinicians to humanly imperceptible patterns in ECG signals, providing an early warning for serious occult or impending disease.

“This stands to improve the lives of people with cardiac amyloidosis by improving the speed of triage and care of this group.”

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact